{"organizations": [], "uuid": "b6ed6af60d901f3e6f77dfaffbb6b9ee41afee62", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-initiates-pha/brief-catalyst-biosciences-initiates-phase-2-3-trial-of-marzeptacog-alfa-idUSASB0BZQR", "country": "US", "domain_rank": 408, "title": "BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T19:42:00.000+02:00", "replies_count": 0, "uuid": "b6ed6af60d901f3e6f77dfaffbb6b9ee41afee62"}, "author": "", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-initiates-pha/brief-catalyst-biosciences-initiates-phase-2-3-trial-of-marzeptacog-alfa-idUSASB0BZQR", "ord_in_thread": 0, "title": "BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)", "locations": [], "entities": {"persons": [{"name": "tri", "sentiment": "negative"}, {"name": "marzeptacog alfa", "sentiment": "none"}], "locations": [], "organizations": [{"name": "marzaa", "sentiment": "none"}, {"name": "catalyst biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 5:44 PM / Updated 7 minutes ago BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated) Reuters Staff 1 Min Read \nJan 4 (Reuters) - Catalyst Biosciences Inc: \n* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS \n* CATALYST BIOSCIENCES INC - ‍INTERIM DATA FOR PHASE 2 MARZAA TRIAL​ EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T19:42:00.000+02:00", "crawled": "2018-01-04T20:06:39.015+02:00", "highlightTitle": ""}